234 related articles for article (PubMed ID: 22956577)
1. Crosstalk between human IgG isotypes and murine effector cells.
Overdijk MB; Verploegen S; Ortiz Buijsse A; Vink T; Leusen JH; Bleeker WK; Parren PW
J Immunol; 2012 Oct; 189(7):3430-8. PubMed ID: 22956577
[TBL] [Abstract][Full Text] [Related]
2. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
3. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
4. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
[TBL] [Abstract][Full Text] [Related]
5. Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation.
Johnson WJ; Steplewski Z; Matthews TJ; Hamilton TA; Koprowski H; Adams DO
J Immunol; 1986 Jun; 136(12):4704-13. PubMed ID: 3711663
[TBL] [Abstract][Full Text] [Related]
6. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
7. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
8. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
10. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a series of isotype switch variants of a new CD20 monoclonal antibody.
Hooijberg E; Sein JJ; van den Berk PC; Hekman A
Hybridoma; 1996 Feb; 15(1):23-31. PubMed ID: 9064283
[TBL] [Abstract][Full Text] [Related]
12. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
Niwa R; Sakurada M; Kobayashi Y; Uehara A; Matsushima K; Ueda R; Nakamura K; Shitara K
Clin Cancer Res; 2005 Mar; 11(6):2327-36. PubMed ID: 15788684
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
14. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
Xia Y; Vetvicka V; Yan J; Hanikýrová M; Mayadas T; Ross GD
J Immunol; 1999 Feb; 162(4):2281-90. PubMed ID: 9973505
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
16. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
17. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.
Parren PW; Warmerdam PA; Boeije LC; Arts J; Westerdaal NA; Vlug A; Capel PJ; Aarden LA; van de Winkel JG
J Clin Invest; 1992 Oct; 90(4):1537-46. PubMed ID: 1401085
[TBL] [Abstract][Full Text] [Related]
18. Exogenous C1q reconstitutes resident but not inflammatory mouse peritoneal macrophages for Fc receptor-dependent cellular cytotoxicity and phagocytosis. Relationship to endogenous C1q availability.
Leu RW; Zhou AQ; Rummage JA; Kennedy MJ; Shannon BJ
J Immunol; 1989 Nov; 143(10):3250-7. PubMed ID: 2809201
[TBL] [Abstract][Full Text] [Related]
19. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
Patel D; Guo X; Ng S; Melchior M; Balderes P; Burtrum D; Persaud K; Luna X; Ludwig DL; Kang X
Hum Antibodies; 2010; 19(4):89-99. PubMed ID: 21178280
[TBL] [Abstract][Full Text] [Related]
20. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.
Schneider-Merck T; Lammerts van Bueren JJ; Berger S; Rossen K; van Berkel PH; Derer S; Beyer T; Lohse S; Bleeker WK; Peipp M; Parren PW; van de Winkel JG; Valerius T; Dechant M
J Immunol; 2010 Jan; 184(1):512-20. PubMed ID: 19949082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
